Did Exelixis beat or miss consensus estimates last quarter?

What is Exelixis's gross profit margin?

What factors drove the changes in Exelixis's revenue and profit?

What were the key takeaways from Exelixis’s earnings call?

What is Exelixis's latest dividend and current dividend yield?

What does Exelixis do and what are its main business segments?

What is the market's earnings forecast for Exelixis next quarter?

What is the revenue and EPS growth rate for Exelixis year over year?

- **Revenue Growth**: U.S. cabo franchise up 17% to $2.12B in 2025, driven by NET expansion and RCC leadership.
- **Zanza Milestone**: Zanzalintinib NDA accepted for CRC, targeting December 2026 PDUFA date.
- **Commercial Expansion**: GI sales team doubled to capitalize on NET growth and zanza launch readiness.
- **Pipeline Momentum**: 7 zanza trials underway, including MRD+ CRC and non-clear cell RCC studies.
- **Financial Strength**: $1.66B cash, $590M remaining under $750M share repurchase program.
- **Strategic Focus**: Build multi-franchise oncology business in solid tumors with product, indication, and modality leadership.

**【CEO Summary Section】**
- Exelixis achieved a transformative year in 2025 with 17% growth in U.S. cabo franchise net product revenues to $2.12 billion.
- Zanzalintinib (zanza) NDA accepted for CRC, targeting a PDUFA date of December 2026.
- Expanded GI sales team to capitalize on neuroendocrine tumor (NET) growth and prepare for zanza launch.
- Franchise strategy focuses on product, tumor indication, and modality leadership in solid tumor oncology.

**【CFO Financial Commentary】**
- Q4 2025 total revenues: $599 million, with cabo net product revenues at $546.6 million.
- Full year 2026 gross to net estimate: 31-32%, including 2% Medicare discount.
- Share repurchases: $954 million in 2025, with $590 million remaining under $750 million authorization.
- GAAP net income: $244.5 million (Q4 2025), non-GAAP EPS: $0.97.

**【Commercial Update】**
- CABOMETYX maintains #1 TKI position in RCC and NET, with 46% TRx share in Q4 2025.
- NET revenue exceeds $100 million in 2025, targeting community oncology expansion.
- Zanza launch preparation includes team expansion and partnerships with Merck for pivotal trials.

**【R&D Pipeline】**
- Zanza has 7 ongoing/pivotal trials, including STELLAR-303 (NDA accepted) and STELLAR-316 (MRD+ CRC trial).
- Early-stage pipeline includes 4 clinical molecules (XL309, XB010, XB628, XB371).
- Collaborations with Merck (belzutifan) and Natera (ctDNA diagnostics) enhance development strategy.

**【Q&A Highlights】**
- Zanza launch timing hinges on FDA review; potential 2026 CRC approval and subsequent RCC trials.
- NET market share growth driven by community oncology expansion and 20%+ annual revenue trajectory.
- 2026 financial guidance includes $750 million share repurchase program and 31-32% gross to net.
- Zanza's franchise potential supported by TAM/MET mechanism and combination IO trials.

**【Strategic Priorities】**
- Accelerate zanza development in CRC, RCC, and NET with 7+ pivotal trials.
- Maintain cabo leadership in RCC and NET through commercial team expansion and data-driven insights.
- Pipeline diversification with early-stage assets targeting solid tumor franchises.
- Capital allocation focused on R&D, external partnerships, and shareholder returns.


Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript

- **CABO Franchise Growth**: Q3 CABO revenue $543M (+14% YoY), global franchise $739M (+13% YoY), NET indication driving 6% of total demand.
- **ZANZA Breakthrough**: STELLAR-303 CRC trial met primary endpoint (HR 0.80, p=0.0045), with 10.9-month OS vs 9.4 months for regorafenib.
- **Financial Strength**: Non-GAAP EPS $0.81, $1.6B cash, $750M buyback authorization, and 2025 revenue guidance narrowed to $2.3-2.35B.
- **Strategic Expansion**: GI sales team expansion for NET and ZANZA, with 2026 CRC adjuvant trial启动.

**【CEO Summary Section】**
- Exelixis reported strong Q3 2025 performance with CABO franchise net product revenue of $543M, up 14% YoY. Global CABO franchise revenue reached $739M, up 13% YoY.
- ZANZA combination with atezolizumab achieved statistical significance in STELLAR-303 CRC trial (HR 0.80, p=0.0045), with 10.9-month median OS vs 9.4 months for regorafenib.
- Expanded GI sales team to accelerate CABO NET growth and prepare for ZANZA launch in CRC.

**【CFO Financial Commentary】**
- Total Q3 revenue $598M, including $543M CABO franchise. Non-GAAP net income $218M ($0.81 EPS), up 24% YoY.
- Repurchased $99M shares (2.4M shares) in Q3, with $750M new buyback authorization approved.
- Updated 2025 guidance: Total revenue $2.3-2.35B, R&D $850-900M, tax rate 17-18%.

**【R&D & Commercial Updates】**
- STELLAR-303: ZANZA + atezo demonstrated 20% OS benefit in ITT CRC population, with 15.9-month OS in NLM subgroup.
- CABO NET launch achieved >40% new patient share in Q3, contributing 6% of total demand.
- ZANZA pivotal trials expanding into recurrent meningioma and adjuvant CRC settings.

**【Q&A Highlights】**
- ZANZA CRC positioning: 75% of U.S. CRC patients receive prior bevacizumab, aligning with ZANZA's bev-pretreated subgroup (10.5-month OS).
- STELLAR-304 trial design: Sunitinib comparator chosen due to its global standard of care status in non-clear cell RCC.
- NET market dynamics: CABO oral therapy advantage over generic competitors driving 50% QoQ demand growth.
- Capital allocation: Balance R&D ($850-900M), BD, and buybacks ($750M authorized for 2026).

Exelixis, Inc. (EXEL) Q3 2025 Earnings Call Transcript

- **Cabo Franchise Growth**: Q2 U.S. revenues $520M (+19% YoY), NET launch drives 35% new patient share in oral therapies.
- **Zanza Breakthrough**: STELLAR-303 shows OS benefit in CRC, positioning for regulatory filing and potential $3B+ franchise.
- **Pipeline Momentum**: 4 INDs filed in 2025, with XL309, XB010, XB371 advancing into Phase I/II.
- **Financial Strength**: $1.4B cash, $302M shares repurchased, Non-GAAP EPS $0.78 beats expectations.
- **Strategic Focus**: Prioritizing high-value zanza indications (adjuvant CRC, NETs) over lower-potential head/neck.

**【CEO Summary Section】**
- Exelixis reported strong Q2 2025 performance with cabozantinib (cabo) U.S. net product revenues growing 19% YoY to $520 million, driven by commercial demand and new NET indications.
- Zanzalintinib (zanza) showed promising Phase III results in colorectal cancer (STELLAR-303), with statistically significant OS improvement vs. regorafenib in ITT population.
- NET launch achieved 35% new patient share in Q2, with CABOMETYX viewed as best-in-class oral therapy.
- Early-stage pipeline advanced with IND filings for XL309, XB010, and XB371, targeting unmet needs in oncology.

**【CFO Financial Commentary】**
- Total Q2 2025 revenues: $568 million (cabo: $520M, collaboration: $48.2M).
- Gross to net rate: 30.2% (up 4ppt YoY due to 340B volume growth to 24% of total).
- Operating expenses: $355 million (down $14M QoQ due to lower manufacturing and clinical costs).
- GAAP net income: $184.8 million; Non-GAAP EPS: $0.78 (exceeding expectations).
- Free cash flow: $1.4 billion; $302 million shares repurchased in Q2.

**【Commercial (P.J. Haley) Highlights】**
- CABOMETYX maintains #1 TKI position in RCC with 45% TRx share (up 4ppt YoY).
- NET launch success: 35% new patient share in oral therapies, with rapid uptake across tumor types.
- 340B channel now 24% of volume, impacting gross margins but reflecting cabo's standard-of-care status.

**【Clinical Development (Amy Peterson)】**
- STELLAR-303: Zanza + atezo demonstrated OS benefit in ITT CRC population; regulatory filing planned.
- STELLAR-304: Non-clear cell RCC trial fully enrolled, with PFS/ORR dual primary endpoints.
- Zanza monotherapy trial (STELLAR-311) initiated in NETs, targeting everolimus replacement.
- Wave 2 opportunities: Adjuvant CRC and meningioma studies planned for 2025-2026.

**【Early-Stage Pipeline (Dana Aftab)】**
- XL309 (USP1 inhibitor), XB010 (5T4 ADC), and XB371 (TF ADC) in Phase I with promising preclinical data.
- XB628 (PD-L1/NKG2A bispecific) enrolling rapidly, leveraging novel dual-cleavage payload release mechanism.
- IND filed for XB371, with potential for deep tumor penetration and durable regressions.

**【Q&A Highlights】**
- STELLAR-303: OS benefit in ITT population validates zanza's IO/TKI combination; NLM subgroup analysis ongoing.
- NET market: 35% new patient share in Q2, with potential for 3x+ growth as patients progress on prior therapies.
- Pricing dynamics: 340B volume growth expected to continue, but commercial execution maintains franchise momentum.
- Zanza prioritization: Adjuvant CRC and meningioma trials (3x higher commercial value) over head/neck due to competitive landscape.


Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript

- **CABOMETYX Growth Accelerates**: Q1 2025 US net product revenues up 36% YoY to $513M, with 44% TRx share in RCC and FDA-approved NET expansion.
- **Pipeline Momentum**: Zanza pivotal trials expected to report in Q3/Q4 2025; XB628 Phase 1 trial recruiting, targeting $179M non-GAAP net income.
- **Capital Allocation**: $289M share buybacks in Q1; $500M new buyback authorization to capitalize on undervalued shares.
- **NET Market Opportunity**: ~$1B annual US opportunity by 2025, with CABOMETYX uniquely positioned as first oral therapy with broad label coverage.
- **Financial Confidence**: Raised 2025 net product revenue guidance by $100M to $2.05-$2.15B, reflecting strong execution and pipeline visibility.

**【CEO Summary Section】**
- Exelixis reported a 36% year-over-year increase in US cabozantinib (CABOMETYX) franchise net product revenues to $513 million in Q1 2025, driven by demand growth and new patient starts.
- Received FDA approval for CABOMETYX in pancreatic and extra-pancreatic neuroendocrine tumors (NETs) on March 26, 2025, expanding its addressable market to ~9,000 US patients in 2025 and ~11,000 by 2030.
- Raised full-year 2025 net product revenue guidance by $100 million to $2.05-$2.15 billion, reflecting strong CABOMETYX performance and expectations for NET launch momentum.
- Advanced zanza (zanzalintinib) into pivotal trials across multiple indications, with top-line data expected in Q3/Q4 2025 for colorectal and non-clear cell RCC.
- Maintained focus on disciplined capital allocation, repurchasing $289 million of shares in Q1 and authorizing an additional $500 million buyback program.

**【CFO Financial Commentary】**
- GAAP net income of $159.6 million ($0.57/share) and non-GAAP net income of $179.6 million ($0.64/share) in Q1 2025, driven by $513 million in CABOMETYX net product revenues.
- Total operating expenses decreased 8% sequentially to $369 million, benefiting from lower clinical trial and manufacturing costs.
- Cash and marketable securities of $1.65 billion as of March 31, 2025, supporting pipeline advancement and share repurchases.
- Projected gross-to-net rate of 29-30% for 2025, stable due to small manufacturer status under Medicare Part D.

**【Commercial Update (P.J. Haley)】**
- CABOMETYX maintained leadership in renal cell carcinoma (RCC) with 44% TRx share in the TKI market basket, up 4pts YoY, and 27% NRx growth.
- NET launch progress: >70% of target prescribers engaged within 3 weeks of approval, with prescribers citing unmet need and oral administration advantage over Lutathera.
- Q1 2025 global CABOMETYX franchise revenue (Exelixis + partners) of $680 million, up 22% YoY.

**【Pipeline Progress (Amy & Dana)】**
- Zanza pivotal trials: STELLAR-303 (colorectal cancer) and STELLAR-304 (non-clear cell RCC) on track for 2025 readouts; STELLAR-311 (NET) initiation expected in Q2.
- IND filings: XB628 (NKG2A/PD-L1 bispecific) Phase 1 trial recruiting; XB371 (tissue factor ADC) and XB064 (ILT2 antibody) INDs expected in 2025.
- Discontinued XL495 (PKMYT1 inhibitor) due to on-target toxicities, reallocating resources to higher-priority programs.

**【Q&A Highlights】**
- NET launch: ~$1 billion US market opportunity in 2025, with 80%+ utilization in second/third-line settings; early prescriber feedback highly positive.
- Zanza statistical design: Dual primary endpoints in STELLAR-303 (NLM and ITT) to maximize patient benefit, no alpha split required.
- Business development: Seeking late-stage assets in GU/GI space with clear commercial pathways, prioritizing pay-for-success models.
- Stock buybacks: Repurchased 19% of float since 2023; will continue when shares are undervalued relative to growth prospects.

Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript

- **CABO Growth Accelerates**: Q4 2024 U.S. net product revenues up 20% YoY to $515M, with global franchise at $2.5B annually.
- **ZANZA Pivotal Trials H2 2025**: Colorectal, non-clear cell kidney, and head-and-neck cancer data expected, alongside NET trial initiation.
- **NET sNDA on Track**: PDUFA date April 3, 2025, with launch readiness and $1B oral market opportunity.
- **Strong Cash Position**: $1.75B in liquidity post-$656M share buybacks, supporting aggressive R&D ($1B FY 2025) and pipeline expansion.
- **ADC Pipeline Expansion**: Three new INDs and Phase I data presentations planned for 2025, targeting unmet oncology needs.

**【CEO Summary Section】**
- Exelixis achieved a breakout year in 2024, with U.S. cabozantinib (CABO) franchise net product revenues growing 20% YoY to $515 million in Q4 2024 and $1.81 billion for the full year. Global CABO franchise revenues reached $690 million and $2.5 billion for Q4 and FY 2024, respectively.
- The company aims for $3 billion in CABO revenue by 2030 and $5 billion in zanzalintinib (ZANZA) revenue by 2033. ZANZA is expected to report pivotal trial results in colorectal, non-clear cell kidney, and head-and-neck cancers in H2 2025.
- The sNDA for CABO in neuroendocrine tumors (NET) has a PDUFA date of April 3, 2025, with the company launch-ready post-approval.
- The IND pipeline includes three new assets (XB628, XB064, XB371) and Phase I trials for XL309, XB010, and XL495, targeting unmet needs in oncology.

**【CFO Financial Commentary】**
- Q4 2024 total revenues were $567 million, with CABO net product revenues at $515.2 million. Non-GAAP net income was $160.3 million, or $0.56 per share.
- Gross-to-net for CABO was 26.8% in Q4, expected to rise to 29-30% in FY 2025 due to Medicare discounts and co-pay assistance.
- Operating expenses (excluding restructuring) rose 14% QoQ to $403 million, driven by R&D and clinical trial costs.
- Cash and marketable securities ended FY 2024 at $1.75 billion, with $656 million in share repurchases.

**【Q&A Key Highlights】**
- **NET Launch Expectations**: P.J. Haley emphasized the $1 billion oral NET market in 2025, with CABO's broad applicability across tumor types and 80% prescriber overlap with current franchise.
- **ZANZA Safety & Dosing**: Amy Peterson highlighted Phase II data showing maintainable dose intensity with checkpoint inhibitors, with safety profile comparable to standard therapies.
- **Capital Allocation**: Mike Morrissey reaffirmed commitment to pipeline prioritization, share buybacks, and strategic M&A, with FY 2025 R&D spend of ~$1 billion.
- **Pipeline Expansion**: Dana Aftab detailed ADC program XB371's differentiation via tissue factor antibody and plans for colorectal cancer trials, alongside three new IND filings in 2025.


Exelixis (EXEL)-11 Feb 25-2024 Q4 Earnings call transcript

- **CABOMETYX Exclusivity Extended**: ANDA ruling secures U.S. sales through early 2030, with potential for further extension via appeal.
- **Zanza Collaboration with Merck**: Accelerates development in kidney and head and neck cancers, targeting annual launches starting 2026.
- **Q3 Financial Strength**: $539.5 million revenue (+15% YoY), $1.7 billion cash, and $500 million buyback program.
- **Pipeline Momentum**: XL-309 and XL-495 Phase I trials underway, targeting synthetic lethality in BRCA and HRD+ cancers.
- **Commercial Leadership**: CABOMETYX 42% TRx share in TKI market, leading all competitors with 9% QoQ growth.

**【CEO Summary Section】**
- Exelixis achieved a favorable ANDA ruling for cabozantinib (CABOMETYX), extending U.S. exclusivity into early 2030. The company is appealing the District Court's judgment to potentially extend exclusivity further.
- Announced a collaboration with Merck for zanzalintinib (Zanza) in kidney and head and neck cancers, leveraging Merck's clinical trial expertise. Zanza is expected to launch annually starting 2026, targeting $5 billion+ U.S. sales by 2033.
- Projected CABOMETYX U.S. peak sales of ~$3 billion by 2030, driven by new indications in neuroendocrine tumors (NETs) and prostate cancer. Global cabozantinib franchise Q3 net product revenue: $653 million (+12% YoY).
- Committed to maintaining R&D investment levels, balancing pipeline advancement with $1.7 billion in cash and a $500 million share buyback program.

**【CFO Financial Commentary】**
- Q3 2024 total revenue: $539.5 million (+15% YoY), with CABOMETYX net product revenue: $478.1 million (+12% YoY). Full-year net product revenue guidance updated to $1.775-$1.825 billion.
- GAAP net income: $118 million ($0.40 EPS); Non-GAAP EPS: $0.47. Operating expenses: $352 million (-2% QoQ) due to lower G&A costs.
- Cash and marketable securities: $1.7 billion. Repurchased $12 million of shares in Q3, with $500 million buyback program remaining.

**【Commercial Performance】**
- CABOMETYX maintains 42% TRx share in the TKI market basket, leading all competitors. Q3 new patient starts and demand at all-time highs, driven by first-line RCC and community oncology growth.
- CABINET study in NETs showed 65% disease control rate, positioning CABOMETYX for regulatory approval in 2025. Zanza's Phase III trials in colon, kidney, and head and neck cancers could expand the oncology franchise into the 2030s.

**【Q&A Highlights】**
- **Merck Collaboration**: Exelixis will co-fund Zanza trials with Merck, maintaining global commercial rights. Trials will leverage Merck's expertise in kidney and head and neck cancers.
- **Pipeline Strategy**: Focused on molecules with differentiated clinical profiles (e.g., XL-309, XL-495) targeting synthetic lethality in BRCA and HRD+ cancers.
- **Capital Allocation**: Balancing R&D investment (~$350 million/year) with shareholder returns via buybacks and dividends.
- **Competitive Positioning**: CABOMETYX's leadership in RCC and GI oncology provides a blueprint for Zanza's expansion into new tumor types.


Actual											0.15	0.21	-0.1	0.09	0	0.3	0.12	0.29	0.21	0.22	0.23	-0.09	0.12	0.25	0	0.27	0.12	0.77	0.4	0.48	0.62	0.75	0.78	0.94
Forecast											0.13	0.1207	0.01	0.0573	0.03	0.0608	0.1955	0.061	0.1422	0.1967	0.1915	-0.1104	0.1606	0.154	0.0979	0.228	0.2221	0.3098	0.3393	0.4255	0.3581	0.6678	0.685	0.8296
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+15.38%	+73.99%	-1100.00%	+57.07%	-100.00%	+393.42%	-38.62%	+375.41%	+47.68%	+11.85%	+20.10%	+18.48%	-25.28%	+62.34%	-100.00%	+18.42%	-45.97%	+148.55%	+17.89%	+12.81%	+73.14%	+12.31%	+13.87%	+13.31%

EXEL

EXEL fundamentals

EXEL Q4 2025 Earnings

Earnings Call

You can ask Aime

EXEL

EXEL fundamentals

EXEL Q4 2025 Earnings

Earnings Call

EXEL Earnings Call Summary for Q4/20255:00 PM on Feb 10, 2026

EXEL Earnings Call Summary for Q3/20255:00 PM on Nov 4, 2025

EXEL Earnings Call Summary for Q2/20255:00 PM on Jul 28, 2025

EXEL Earnings Call Summary for Q1/20255:00 PM on May 13, 2025

EXEL Earnings Call Summary for Q4/20245:00 PM on Feb 11, 2025

You can ask Aime